![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » XOMA SUSPENDS HEPEX-B WORK FOLLOWING CUBIST DECISION
XOMA SUSPENDS HEPEX-B WORK FOLLOWING CUBIST DECISION
July 31, 2006
XOMA Ltd. announced that, in light of Cubist Pharmaceuticals, Inc.'s recently announced decision to cease investment in its HepeX-B product because of stringent FDA requirements for regulatory approval, XOMA has placed its production process development work for Cubist on hold and has issued a notice of contract termination to Cubist. Cubist and XOMA have begun discussions to consider other development
options for HepeX-B.
Genetic
Engineering News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct